Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shinsuke Iida

Showing results (281-290 of 290) with videos related to

Pageof 29
Sort By:
You have reached the last page of results.This site can display upto 290 results.
Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
Blood Advances|February 16, 2021
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trialKen Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, et al.
Cancer|January 4, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohortThomas G Martin, María-Victoria Mateos, Jun Ho Yi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
Cancer Science|July 4, 2020
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility studyTakahiko Yasuda, Masashi Sanada, Dai Nishijima, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Transplantation and Cellular Therapy|May 18, 2026
Vaccine-Induced Anti-HBs Response Is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized TrialMasahiro Onozawa, Shigeru Kusumoto, Yachiyo Kuwatsuka, et al.
Pageof 29

Showing results (281-290 of 290) with videos related to

Sort By:
Pageof 29
You have reached the last page of results.This site can display upto 290 results.
Blood|July 21, 2021
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIAMichele Cavo, Jesus San-Miguel, Saad Z Usmani, et al.
Blood Advances|February 16, 2021
A randomized phase 2/3 study of R-CHOP vs CHOP combined with dose-dense rituximab for DLBCL: the JCOG0601 trialKen Ohmachi, Tomohiro Kinoshita, Kensei Tobinai, et al.
Cancer|January 4, 2026
Efficacy and safety of teclistamab in triple-class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohortThomas G Martin, María-Victoria Mateos, Jun Ho Yi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA StudyRakesh Popat, Meral Beksac, Meletios A Dimopoulos, et al.
Blood Cancer Journal|November 5, 2020
Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUXJonathan L Kaufman, Meletios A Dimopoulos, Darrell White, et al.
Nature Medicine|August 15, 2023
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial resultsAlexander M Lesokhin, Michael H Tomasson, Bertrand Arnulf, et al.
Cancer Science|July 4, 2020
Clinical utility of target capture-based panel sequencing in hematological malignancies: A multicenter feasibility studyTakahiko Yasuda, Masashi Sanada, Dai Nishijima, et al.
Haematologica|September 22, 2018
Daratumumab plus lenalidomide and dexamethasone <i>versus</i> lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUXMeletios A Dimopoulos, Jesus San-Miguel, Andrew Belch, et al.
Blood|August 28, 2024
Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analysesSikander Ailawadhi, Bertrand Arnulf, Krina Patel, et al.
Transplantation and Cellular Therapy|May 18, 2026
Vaccine-Induced Anti-HBs Response Is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized TrialMasahiro Onozawa, Shigeru Kusumoto, Yachiyo Kuwatsuka, et al.
Pageof 29